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Abstract
Background Intramuscular (L-)epinephrine is used as self-
medication for serious hypersensitivity reactions. Inhalative
administration has the theoretical advantage of a more rapid
absorption and better controllability.
Objectives The current trial was conducted to explore phar-
macokinetics and pharmacodynamics of two nebulized
inhalative epinephrine doses (4 mg and 8 mg in aqueous
solution) using a mobile pocket inhaler relative to intramus-
cular administration (0.3 mg) and placebo.
Methods This randomized, open-label, change-over pilot
study involved eight young healthy men and women. Non-
compartmental pharmacokinetic and pharmacodynamic
parameters were calculated from epinephrine plasma con-
centrations and hemodynamic parameters.
Results Mean exposure to epinephrine decreased from the 8mg
dose to the 4 mg inhalative dose, and further with the 0.3 mg
intramuscular dose, with active treatments showing significantly
higher concentrations than placebo (geometric mean area under
the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L).
Maximal concentrations were reached within approximately
15 min for all active treatments. Epinephrine effects for inhala-
tive administrations on heart rates were significantly higher than
those for the intramuscular or placebo administration, while no
excessive effects occurred. Pronounced overall variability pro-
hibited a definite assessment of relative bioavailability between
treatments. However, results indicated that epinephrine concen-
trations obtained following the 8 mg inhalative dose were not
inferior to those after 0.3 mg i.m.
Conclusions A relevant fraction of moist inhalation epi-
nephrine doses is absorbed and mediates systemic effects.
This suggests that administration of epinephrine via a suit-
able pocket inhaler device may be beneficial in ambulatory
emergency treatment of systemic hypersensitivity reactions.
EudraCT number: 2010-021493-11
Keywords Acute allergic reaction . Anaphylaxis .
Epinephrine . Inhalative . Intramuscular
Introduction
Anaphylaxis is a serious allergic reaction that is rapid in
onset and may cause death [1]. In addition to the immediate
termination of further allergen exposure, epinephrine is the
primary medical therapy for life-threatening allergic reac-
tions [2]. Epinephrine antagonizes the symptoms of anaphy-
lactic shock by increasing of heart rate (ß1 adrenoceptors),
myocardial contractility (ß1), and peripheral vascular resis-
tance (α1) by bronchodilatation with increased oxygen
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absorption (ß2) [3–7], and by decreasing further mast cell
release of mediators of inflammation.
Epinephrine has a very low oral bioavailability which
makes this form insufficient for therapeutic use [3–6]. In-
travenous administration is often not feasible. Thus, intra-
muscular (i.m.) administration of epinephrine is used as
first-line treatment and self-medication for serious hyper-
sensitivity reactions, usually at doses of 0.3 mg in the lateral
part of the thigh [3]. Despite the pivotal role of epinephrine
in anaphylaxis, individuals are often reluctant to use self-
injectable epinephrine (e.g. because of anxiety about using a
needle) [8]. It has been reported that only 30–40 % of
individuals in whom anaphylaxis occurred actually received
epinephrine injections [9], and only 32 % of 101 families of
food-allergic children correctly demonstrated the proper use
of the device [10]. Moreover, application errors (e.g. intra-
digital injection) are common [11, 12]. Furthermore, for i.m.
injection local vasoconstriction and a lowered blood supply
of the muscles in the event of blood pressure drop-off may
impair absorption, causing the effects of the medication to
be delayed and prolonged [3–6].
Thus, there is a medical need for another rapidly acting
route of epinephrine administration for serious hypersensi-
tivity reactions, and to this end, inhalation of epinephrine
might be considered. Inhalative administration offers direct
local activity of epinephrine and rapid absorption. In partic-
ular, epinephrine inhalation is considered useful for anaphy-
lactic reactions of the respiratory tract, but bioavailability
studies of epinephrine inhalation are sparse in general and
limited to metered dose inhaler applications that have been
withdrawn from the market [13].
INFECTOKRUPP® Inhal (marketed in Germany) is an
epinephrine solution for the treatment of allergic reactions of
the upper airways containing 4 mg/mlL-epinephrine-HCl. It
is currently indicated for acute dyspnoea in upper airway
obstruction, especially laryngotracheobronchitis and allergic
reactions [4]. In this method, epinephrine doses of up to
8 mg are inhaled [14]. The aim of this study was to inves-
tigate potential suitability of the administration of INFEC-
TOKRUPP® Inhal by using a new battery driven mobile
pocket inhaler (INFECTOPHARM Taschenvernebler,
Omron Microair U22) for the treatment of acute allergic
reactions in emergency situations. Thus, we explored phar-
macokinetics and pharmacodynamics of 4 mg and 8 mg
moist inhalation epinephrine doses relative to intramuscular
administration (Anapen® 300 μg) and placebo inhalation.
Methods
The trial was conducted according to the principles of Good
Clinical Practice [15] and in accordance with the ethical
principles of the Declaration of Helsinki [16]. Approval
was provided by the Ethics Committee of the Medical
Association of North Rhine, Germany and the competent
authority (EudraCT-number 2010-021493-11). Written in-
formed consent was obtained from all participants.
This pilot trial was designed as a single site, randomized,
placebo-controlled, open-label, four arm change-over study.
The trial population comprised nine healthy Caucasians,
aged between 28 and 53 years, weighing 60 kg or higher
with a Body Mass Index of 19–29 kg/m2. Dosing was done
in a fasting state with the subjects in supine position with the
upper half of the body semi-elevated, and at the same time
in the morning for all treatments. In respective study peri-
ods, each participant received one of the following treat-
ments as a single dose:
& Treatment A (reference): Anapen® (Dr. Beckmann
Pharma GmbH, Seefeld, Germany), i.m. administration
of 0.3 mL solution equivalent to 0.3 mg of epinephrine
using the respective pen applicator placed at the antero-
lateral part of the musculus quadriceps femoris (appli-
cation carried out and checked by a trained physician)
& Treatments B or C (test treatments): INFECTOKRUPP®
Inhal (Infectopharm Arzneimittel und Consilium GmbH,
Heppenheim, Germany), inhalative administration of 1
or 2 mL solution equivalent to 4 and 8 mg of L-
epinephrine, respectively
& Treatment D (placebo): NaCl Inhalationslösung 0,9 %
(PARI GmbH, Starnberg, Germany) inhalative adminis-
tration of 2 mL solution, containing 0.9 % of sodium
chloride in water
All inhalative treatments were administered using the
Infectopharm Taschenvernebler® (Infectopharm Arzneimit-
tel und Consilium GmbH, Heppenheim, Germany, identical
to Omron Microair U22, Omron HealthcareEurope, Hoofd-
dorp, The Netherlands), set to the on–off modus for the
inhalation–exhalation procedure. The inhaler is character-
ized by a volumetric median particle diameter of 5.7±
0.06 μm, an inhalable fraction which is similar to the fine
particle fraction of 40±1 %, and delivered doses of 27.5±
0.2 % for 1 ml and 28.8±0.6 % for 2 ml administration
volume, respectively (Infectopharm Arzneimittel und Con-
silium GmbH, data on file). Extensive training sessions were
performed prior to dosing with each subject to safeguard
correct use of the inhaler.
For the quantification of epinephrine in plasma, specific
ClinRep® blood collection tubes were used (Recipe Chem-
icals and Instruments GmbH, München, Germany). Blood
samples were taken from a catheter inserted beforehand
three times before dosing and every minute following the
start of administration up to 12 min, as well as 15, 20, 25,
30, 45, 60, 90, 120, 150 and 180 min. Blood samples were
centrifuged at 4 °C and plasma was stored at −20 °C until
analysis. The quantification of epinephrine was carried out
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using a validated, analytical high performance liquid
chromatography-tandem mass spectrometry (HPLC-MS)
method. The internal standard 1,2-13C DL-epinephrine was
added to plasma, and samples were extracted using Recipe®
sample preparation columns. Eluted samples were separated
on a Phenomenex KinetexTM column (Phenomenex,
Aschaffenburg, Germany) at 20 °C using ammonium
formiate-buffer / acetonitrile as the mobile phase. The MS
ion source ESI was used at positive SIM mode. The lower
limit of quantification (LLOQ) was 25 ng/L. Precision
(coefficients of variation) and accuracy (bias) ranged be-
tween 1.6 % – 8.5 % and −7.6 % – 9.0 %, respectively.
Vital signs (systolic and diastolic blood pressure (BP) and
heart rate (HR)) were measured oscillometrically prior to
dosing, continuously from the start until 12 min after dosing
and after each blood sampling (Dinamap™; Criticon,
Tampa, FL, USA).
For calculations, concentrations below the LLOQ were
set to ½ LLOQ (12.5 ng/L). Based on individual plasma
concentrations (without baseline correction), AUC0-t(last),
Cmax (primary pharmacokinetic parameters), AUC0.5h,
AUC1.0h, AUC1.5h, tmax, and MRTlast (secondary pharmaco-
kinetic parameters) values were determined. In addition, the
following pharmacodynamic parameters were calculated:
Emax, AUEC0.5h, AUEC1.0h, AUEC1.5h and AUEClast for
systolic and diastolic blood pressure and for heart rate
(MRT: mean residence time, AUC: area under the curve,
AUEC: area under the effect curve; indices apply for inter-
val from (start of) dosing until the respective post-dose point
of time).
Pharmacokinetic and pharmacodynamic parameters were
calculated by noncompartmental methods and summarized
by descriptive statistics. Comparison between treatments
was done using the average bioavailability approach. To
this end, an ANOVA with the factors sequence, subject
(sequence), period, and treatment was performed for un-
transformed (only tmax) or log-transformed (all other param-
eters) data. The least-squares geometric means from the
ANOVA were used to calculate the ratios and their 90 %
confidence intervals (CIs) between corresponding treat-
ments. The mean square error of the ANOVA was used as
a variance estimate to calculate the 90 % CI around the point
estimate of the true ratio for test (i.e. the two inhalative
doses) relative to reference (i.m. administration) or placebo.
Pharmacokinetic and bioavailability calculations were done
using the WinNonlin® software Version 5.2 (PHARSIGHT
Corporation, Mountain View, California, USA). All other
analyses were performed using SAS® Version 9.1.3 or
higher (SAS Institute, Cary, NC, USA). Primary compari-
sons were made between treatments B and C vs. A for main
characteristics. Secondary comparisons included other
parameters and comparisons to the placebo period. For the
test over reference and/or test over placebo ratios, values of
70 % and 143 % were considered as lower and upper
boundaries for “no relevant difference” between treatments.
Statistically significant differences indicating a true effect
irrespective of “relevance” were assumed if unity (i.e.
100 %) was not included in the 90 % confidence intervals
for the treatment ratios. All results were considered as
essentially descriptive because of the explorative pilot char-
acter of the study.
Results
Five male and three female healthy Caucasians completed
the study. One subject dropped out because of difficulties
with blood sampling. Duration of inhalation grouped by
treatment is shown in Table 1.
Pharmacokinetic results
Pharmacokinetics of the subjects who completed the trial are
shown in Table 1 (further data are provided in the supple-
mentary material). Plots of median epinephrine plasma con-
centrations versus time profiles of epinephrine grouped by
treatment are shown in Fig. 1.
Following epinephrine administration, a rapid increase in
drug plasma concentrations could be observed in all active
treatment periods. Plasma epinephrine concentrations de-
clined rapidly and in most subjects reached the pre-dose
levels or were below the LLOQ at 0.75–1.00 h post-dose.
Mean exposure to epinephrine as derived from Cmax, partial
AUCs and AUC0-t(last) was highest for the 8 mg inhalative
dose and decreased from the 4 mg inhalative dose to the
0.3 mg i.m. dose, with all active treatments being signifi-
cantly higher than placebo (Table 1, Fig. 1).
Pharmacodynamic results
In response to the administration of the study medication,
heart rate increased, while blood pressure values were es-
sentially unchanged (Table 1, see also supplementary mate-
rial). The median effect on heart rate increased from placebo
to 0.3 mg epinephrine as i.m. injection over 4 to 8 mg
inhalative epinephrine (Fig. 2). HR decreased approximate-
ly to baseline values at about 1 h postdose, corresponding to
the decline in epinephrine plasma concentrations.
Detailed comparison between treatments
The mean values of Cmax and AUC0-t(last) were considerably
higher following inhalative epinephrine administrations
compared to placebo. While statistically the high variability
prevents rejection of the assumption that Cmax values have
relevant differences to placebo in any direction, significantly
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higher values for treatments B and C were observed with
regard to AUC0-t(last) and partial AUCs (Table 2, Fig. 3).
Both Cmax and AUC0-t(last) values were higher when 4 or
8 mg epinephrine was administered via inhalation compared
to administration of 0.3 mg epinephrine as i.m. injection.
Ninety percent confidence intervals (CIs) of the ratios were
all outside a 70–143 % range, thus relevant differences be-
tween treatments could not be excluded for these parameters
(Table 2). Secondary pharmacokinetic variables confirm the
results for the primary variables (Table 2, Fig. 3). The pro-
nounced overall variability also prohibited a definite assess-
ment of relative bioavailability between active treatments.
Table 1 Descriptive statistics of pharmacokinetic and pharmacodynamic parameters following epinephrine administration grouped by treatment
(uncorrected values, per protocol population of n=8)
Parameter 0.3 mg i.m. geometric
mean (CV %)
4 mg inhal. geometric
mean (CV %)




Cmax [ng/L] 484 (162) 513 (220) 769 (78.9) 252 (559)
tmax [hr]
a 0.22 (0.25) 0.29 (0.31) 0.21 (0.13) 0.11 (0.11)
AUC0-0.5h [ng*hr/L] 70.7 (113) 108 (230) 162 (47.9) 24.0 (131)
AUC0-1h [ng*hr/L] 130 (78.9) 148 (187) 215 (43.6) 40.0 (100)
AUC0-1.5h [ng*hr/L] 156 (72.4) 177 (164) 233 (43.8) 50.8 (84.6)
AUC0-tlast [ng*hr/L] 204 (66.6) 236 (129) 282 (43.2) 81.6 (58.5)
MRTlast [hr] 0.899 (29.5) 0.860 (34.6) 0.721 (19.3) 1.11 (40.8)
Duration of inhalation [min]a Not applicable 18.0 (5.90) 27.0 (2.45) 16.9 (2.23)
Heart rate Emax [bpm] 78.0 (10.8) 88.2 (8.43) 89.2 (10.9) 87.4 (23.0)
Heart rate AUEC0-0.5h [bpm*hr] 32.9 (8.50) 38.4 (11.8) 39.1 (7.80) 32.5 (8.31)
Heart rate AUEC0-1h [bpm*hr] 65.1 (8.25) 70.8 (10.4) 74.2 (7.45) 64.7 (6.30)
Heart rate AUEC0-1.5h [bpm*hr] 96.4 (7.44) 103 (11.3) 108 (9.65) 96.3 (10.2)
Heart rate AUEC0-tlast [bpm*hr] 191 (6.69) 200 (9.81) 204 (10.2) 185 (8.49)
Systolic BP Emax [mm Hg] 131 (12.5) 133 (8.76) 135 (9.60) 133 (7.92)
Systolic BP AUEC0-tlast [mm Hg*hr] 338 (9.18) 343 (11.0) 343 (9.83) 344 (9.65)
Diastolic BP Emax [mm Hg] 76.2 (10.6) 77.5 (10.3) 75.7 (10.1) 80.2 (14.4)
Diastolic BP AUEC0-tlast [mm Hg*hr] 202 (7.38) 204 (8.73) 205 (8.94) 211 (10.6)
a arithmetic means and standard deviations (SD); AUC area under the concentration vs. time profile (indices apply for the postdose time interval);
AUEC area under the effect curve; Cmax maximal concentration; Emax maximal effect; MRTlast mean residence time calculated from concentrations































0.0 0.5 1.0 1.5 2.0 2.5 3.0
scheduled time relative to (onset of) dosing [hours]
A: 0.3 mg epinephrine i.m.
B:4 mg epinephrine inhalative
C:8 mg epinephrine inhalative
D: placebo
Fig. 1 Median epinephrine plasma concentration versus time profiles
grouped by treatment (n=8) following administration of inhaled or
intramuscular epinephrine or placebo. The time axis refers to the
























0.0 0.5 1.0 1.5 2.0 2.5 3.0
scheduled time relative to (onset of) dosing [hours]
A: 0.3 mg epinephrine i.m.
B:4 mg epinephrine inhalative
C:8 mg epinephrine inhalative
D: placebo
Fig. 2 Median heart rate versus time profiles grouped by treatment (n
=8) following administration of inhaled or intramuscular epinephrine
or placebo. The time axis refers to the injection and/or to the start of
inhalation
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However, non-inferiority in drug exposure of 8 mg epineph-
rine via inhalation compared to 0.3 mg i.m. injection was
indicated with regard to truncated and complete AUC values
(Table 2, Fig. 3; see also supplementary material).
The comparison of pharmacodynamic parameters derived
from heart rate values clearly showed significantly higher
values for the 4 or 8 mg epinephrine inhalations compared
to 0.3 mg i.m. injection, while the entire confidence inter-
vals were always completely within the predefined “no
relevant difference” boundaries of 0.7–1.43. While clinical
translation of these formal boundaries may be debatable, the
magnitude of both mean and maximal heart rate effects
suggests that these do not generate a safety concern for
inhalative epinephrine administration (Table 2).
Figure 3 illustrates the comparison between treatments
for the parameter expected to be most representative and
sensitive to treatment differences, i.e. the AU(E)C for the
initial 30 min after (start of) administrations.
In summary, pharmacokinetic bioequivalence between
inhalative and i.m. preparations could not be proven, while
the assumption of relevant pharmacodynamic differences
could formally be rejected based on the predefined criteria.
A closer look however indicates that concentrations
obtained following 8 mg inhalative dose are at least not
relevantly inferior to those after 0.3 mg i.m. injection (i.e.
the lower limit of the 90 % CI is above 70 %), while changes
in heart rate do not include unity, suggesting that the effects
of inhaled epinephrine exceeds those of i.m. epinephrine,
Table 2 Comparison of pharmacokinetic and pharmacodynamic parameters of epinephrine for inhalative administration (B: 4 mg, C: 8 mg)









Cmax 106.01 158.95 203.40 304.98
(48.23–232.97) (72.32–349.32) (61.37–674.19) (92.01–1010.89)
AUC0-0.5h 152.21 229.28 448.72 675.93
(78.12–296.59) (117.67–446.76) (211.85–950.46) (319.12–1431.70)
AUC0-1h 113.72 165.80 369.01 538.00
(66.86–193.41) (97.49–281.99) (192.37–707.81) (280.48–1031.98)
AUC0-1.5h 113.06 149.11 348.13 459.12
(68.08–187.78) (89.78–247.65) (191.12–634.13) (252.05–836.29)
AUC0-tlast 115.83 138.15 289.64 345.46
(73.19–183.28) (87.30–218.61) (177.26–473.27) (211.42–564.48)
MRTlast 95.76 80.27 77.61 65.05
(78.85–116.28) (66.10–97.47) (58.97–102.13) (49.43–85.61)
Heart rate Emax 113.15 114.34 100.98 102.04
(107.16–119.47) (108.29–120.73) (90.17–113.09) (91.12–114.28)
Heart rate AUEC0-0.5h 116.78 118.96 117.96 120.16
(109.29–124.78) (111.33–127.11) (113.07–123.06) (115.18–125.36)
Heart rate AUEC0-1h 108.77 114.07 109.42 114.74
(104.11–113.65) (109.18–119.18) (105.68–113.29) (110.82–118.81)
Heart rate AUEC0-1.5h 107.20 111.79 107.32 111.91
(103.76–110.76) (108.20–115.50) (101.31–113.69) (105.65–118.55)
Heart rate AUEC0-tlast 104.56 106.81 108.03 110.35
(102.46–106.71) (104.66–109.00) (103.19–113.10) (105.40–115.52)
Systolic BP Emax 101.76 103.13 99.66 101.00
(92.70–111.72) (93.94–113.22) (94.75–104.82) (96.02–106.23)
Systolic BP AUEC0-tlast* 101.45 101.36 99.70 99.60
(95.37–107.92) (95.28–107.83) (96.18–103.34) (96.09–103.25)
Diastolic BP Emax 101.67 99.24 96.59 94.28
(95.75–107.95) (93.47–105.37) (92.33–101.06) (90.12–98.64)
Diastolic BP AUEC0-tlast* 101.19 101.41 96.88 97.09
(96.29–106.35) (96.50–106.58) (93.23–100.68) (93.44–100.89)
AUC area under the concentration vs. time profile (indices apply for the postdose time interval); AUEC area under the effect curve; Cmax maximal
concentration; Emax maximal effect; MRTlast mean residence time calculated from concentrations up to the last point of observation; BP blood
pressure; *blood pressure did not show consistent differences between treatments, fractional AUECs are presented in the Supplementary Material
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without reaching a magnitude suggestive of excessive car-
diac risk.
Safety results
Overall, the study medication was well tolerated. The
frequency of treatment-emergent adverse events (TEAEs)
including those causally related to the trial drug admin-
istration (adverse drug reaction, ADRs) was higher fol-
lowing Treatments B and C compared to Treatment A
and Placebo D. However, the nature and intensity of
TEAEs (n=77) and ADRs (n=37, most assessed as mild)
was very similar between treatments Most of these ad-
verse events occurred within minutes after the start of
epinephrine administration and were of short duration.
They reflected the known pharmacological effects such
as tremor, palpitations, dizziness, tension or fear and
headache. No local mucosal adverse effects at the site
of epinephrine inhalation were reported by the volunteers.
No serious adverse events occurred.
Despite the relatively high inhalative doses of epineph-
rine applied in the study and significantly higher HRs as
a manifestation of epinephrine hemodynamic effects fol-
lowing Treatments B and C, there were no excessive
changes putting subjects at unacceptable risk. During
the trial, there were no cases when inhalation should be
stopped due to an unacceptable rise in systolic BP or in
HR. Maximum observed values were 130 bpm for HR
(following placebo) and 159 mmHg for systolic BP (fol-
lowing inhalation of the 8 mg dose).
Discussion
This trial shows that inhalative administration of epineph-
rine using the combination of a marketed epinephrine solu-
tion with a mobile inhaler can effectively deliver the drug
into the systemic circulation. The results indicate that epi-
nephrine plasma concentrations and haemodynamic (HR)
effects of 8 mg inhalative epinephrine dose are at least not
inferior to those following a 0.3 mg epinephrine dose as i.m.
injection, without causing relevant differences in the nature
and severity of adverse effects. The high inhalative doses in
comparison to intramuscular doses were required because of
the reportedly low bioavailablity of inhalative epinephrine
(see below).
Pharmacokinetic data on inhalative epinephrine is limit-
ed, and existing studies used metered-dose aerosols. There-
fore one might suppose that a high fraction of epinephrine
was swallowed, especially when not using spacers. As
shown by several authors [17–21], inhaled epinephrine is
Table 3 Doses and plasma concentrations of epinephrine reported in clinical pharmacology trials
Reference Healthy
volunteers
dose Cmax ΔHR* ΔSBP* Limitations
(17) 8 3.0 mg pressurized aerosol 400 ng/L + 12 bpm + 10 mmHg Epinephrine absorption was less
complete and shorter in duration
than by sc injection
(18) 12 1.5 mg metered-dose aerosol 500 ng/L (5 min) + 10 bpm not presented Gastrointestinal side effects were
dose-limiting3.0 mg metered-dose aerosol 1300 ng/L (20 min) + 12 bpm not presented
(20) 6 2.4 mg pressurized aerosol 300 ng/L (1 min) + 9 bpm not done Systemic absorption was more
variable after inhalation than
with sc administration
4.8 mg pressurized aerosol 800 ng/L (1 min) + 9 bpm not done
(19) 9 3.0 mg aerosol spray inhalation 2300 ng/L (1 min)
arterial plasma
conc.
+ 15 bpm + 10 mmHg Not presented
(21)* 19** 0.078 mg/kg pressurized
metered-dose inhaler
1822 ng/L (32.7 min) not presented not presented High number of inhalations
required, bad taste
*Data are given as means, ΔHR: change in heart rate, bpm: beats per minute, ΔSBP: change in systolic blood pressure
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Fig. 3 Comparison of the areas under the concentration or heart rate
vs. time profiles for the first 30 min after (start of) inhalative epineph-
rine treatment relative to intramuscular administration and placebo.
Bars indicate 90 % CIs and point estimates for the respective ratios
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absorbed rapidly and in a dose dependent manner in the
airways, and is also rapidly eliminated. Inhalation of epi-
nephrine was reported to increase plasma concentrations
accompanied by tachycardia and a raise in systolic blood
pressure (Table 3) comparable to epinephrine injection.
According to the time course of plasma concentrations, the
pharmacodynamic effects of inhaled epinephrine tended to
be dose dependent and were short-lasting. Pharmacokinetic
results of the moist inhalation of epinephrine of this trial
provide plasma concentrations which are in the same order
of magnitude to those reported in previous studies in healthy
volunteers with other inhalative systems (Table 3). Side
effects or limitations like those reported in references 17–
21 were not observed (Table 3).
In healthy volunteers with normal blood pressure,
changes in HR rather than in systolic and diastolic BP
appear to be more sensitive because blood pressure is reg-
ulated by numerous compensatory mechanisms of which
modifying HR is an important one [17, 19, 22]. Further-
more, the vasodilatory effect of epinephrine via β2-adreno-
ceptors may have indirectly contributed to the increase in
heart rate. Finally, a direct effect on cardiac β-adrenoceptors,
which would be caused by higher local concentrations of
epinephrine upon inhalative administration, cannot be ex-
cluded. This may explain why in the present study pharma-
codynamic effects were limited to heart rate changes, while in
other studies an increase in blood pressure was also seen
(Table 3). The more pronounced tachycardia for the inhala-
tive administration also suggests that concentration in venous
blood samples may not be able to fully capture local concen-
trations in the lung and in the heart.
Usually use of epinephrine immediately after allergen
exposure is effective in the treatment of anaphylaxis. In
the first-aid treatment of anaphylaxis, delay in epinephrine
administration increases the risk for fatal outcomes includ-
ing death [23–26]. The present study supports the idea that
inhalative administration may be an alternative to intramus-
cular administration. Individuals are often reluctant to use
self-injectable epinephrine [27–30], therefore compliance of
epinephrine autoinjectors could be inferior to epinephrine
inhalers and thus inhalation often would be confronted with
non-therapy. Here, continuous inhalative administration of
epinephrine seems to provide appropriate systemic exposure
within several minutes, persisting longer after prolonged
inhalation of the 2 ml dose. In addition, administration of
inhaled epinephrine appears to be safe and it is well con-
trollable in case of adverse effects because any further
systemic exposure can be stopped immediately. There are
some intrinsic limitations for the inhalative use of epineph-
rine as studied here, because the patient needs to be able to
apply an appropriate inhalation technique and to maintain a
sufficient duration of the inhalation. The high variability of
plasma epinephrine concentrations across the subjects may
in part be caused by administration technique or inter-
individual variability of absorption rate and inactivation. Its
clinical relevance remains to be assessed. On the other hand, it
has to be emphasized that the onset after epinephrine inhala-
tion was as fast as for the i.m. application route. In addition,
patients may be less reluctant to use an inhalative system upon
exposure to an allergen prior to the development of symptoms
and may continue or repeat dosing as required.
In conclusion, this primarily exploratory trial indicates that
following administration of 4 or 8 mg of L-epinephrine
(INFECTOKRUPP® Inhal) via inhalation using the “INFEC-
TOPHARM Taschenvernebler”, at least equal systemic expo-
sure and more pronounced pertinent hemodynamic effects
with a similar tolerability profile can be achieved compared
to 0.3 mg epinephrine (Anapen®) as i.m. injection. These data
suggest that moist inhalative epinephrine administration via a
suitable inhaler device may provide therapeutic efficacy in
ambulatory emergency treatment of.systemic hypersensitivity
reactions. It remains to be studied whether this approach is
appropriate in a wider population of patients.
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